Mayo Clinic proceedings · 2025
Benign Prostatic Hyperplasia Increases Long-term Chronic Kidney Disease Risk.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ouyang Chenxi, Zhou Liang, Liu Jiahao, Wang Long, Lu Yao
Аннотация
OBJECTIVE: To assess the long-term association between benign prostatic hyperplasia (BPH) and chronic kidney disease (CKD) while considering the potential role of BPH medications in any observed associations.
METHODS: This study used a prospective cohort design. A total of 198,399 male patients without CKD at baseline were recruited from the UK Biobank from 2006 to 2010. Cox proportional hazards models were used to analyze the relationships between BPH, its medication, and the incidence of CKD and end-stage kidney disease (ESKD).
RESULTS: After a median follow-up of 13.58 years, 3710 patients with BPH were diagnosed with CKD (hazard ratio [HR], 1.26; 95% CI, 1.10 to 1.45), and 322 patients with BPH were diagnosed with ESKD (HR, 1.49; 95% CI, 0.72 to 3.08), compared with non-BPH patients. Furthermore, BPH medication significantly increased the risk of CKD (HR, 1.48; 95% CI, 1.18 to 1.85) in individuals with BPH compared with those without medication.
CONCLUSION: This study found that people with BPH and those taking BPH medications have a higher long-term risk of CKD. Benign prostatic hyperplasia may contribute to the progression of CKD to ESKD. These findings highlight the importance of monitoring kidney function in patients with BPH.
METHODS: This study used a prospective cohort design. A total of 198,399 male patients without CKD at baseline were recruited from the UK Biobank from 2006 to 2010. Cox proportional hazards models were used to analyze the relationships between BPH, its medication, and the incidence of CKD and end-stage kidney disease (ESKD).
RESULTS: After a median follow-up of 13.58 years, 3710 patients with BPH were diagnosed with CKD (hazard ratio [HR], 1.26; 95% CI, 1.10 to 1.45), and 322 patients with BPH were diagnosed with ESKD (HR, 1.49; 95% CI, 0.72 to 3.08), compared with non-BPH patients. Furthermore, BPH medication significantly increased the risk of CKD (HR, 1.48; 95% CI, 1.18 to 1.85) in individuals with BPH compared with those without medication.
CONCLUSION: This study found that people with BPH and those taking BPH medications have a higher long-term risk of CKD. Benign prostatic hyperplasia may contribute to the progression of CKD to ESKD. These findings highlight the importance of monitoring kidney function in patients with BPH.